Stop TB Partnership

Experience sharing workshop on the introduction of new drugs for drug-resistant TB in the WHO European Region


23 September 2015 - Copenhagen, Denmark -- Today marked the end of a two-day joint WHO EURO-HQ meeting that focussed on sharing experiences on the introduction of new drugs for drug-resistant TB treatment in the WHO European Region in Copenhagen, Denmark.

The workshop aims to provide an update on current WHO policy recommendations on the use of new drugs, as well as those in Group V, in the treatment of drug-resistant TB patients, and how to introduce the drugs into programmatic use.

It allows countries and partner organizations which have introduced new and/or repurposed drugs for the treatment of drug-resistant patients to share their experiences, and to plan the next steps in the introduction of these drugs for the treatment of drug-resistant TB patients in the countries of the WHO European Region.

New drugs approved by regularly authorities, notably bedaquiline and delamanid, as well as repurposed drugs classified as Group V by WHO are increasingly being introduced in the treatment regimens for multidrug-resistant and extensively drug-resistant TB patients. WHO’sGlobal TB Programme issued interim policy guidance on the use of bedaquiline in the treatment of MDR-TB in mid-2013 and on the use of delamanid in October 2014. However limited data, particularly on safety, are currently available on these new drugs, and also on the safety and efficacy of the repurposed drugs listed under Group V. It is therefore imperative that adequate provisions for safe, rational and effective use of these drugs be put in place, specifically ensuring appropriate selection of eligible patients, informed consent, design of effective regimens, and close patient monitoring and evaluation.